Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for MYFORTIC
- PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
- Haplo Peripheral Blood Sct In GVHD Prevention
- Veloxis de Novo Kidney Transplant ECSWD
- A Blood Stem Cell Transplant for Sickle Cell Disease
- Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
- Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients
- Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
- To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
- Treg Therapy in Subclinical Inflammation in Kidney Transplantation
- Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients
- Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
- Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation
- Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)
- Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients
- Simulect Versus ATG in Sensitized Renal Transplant Patient
- Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
- Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic A
- Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
- Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
- Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
- Belatacept in Kidney Transplantation of Moderately Sensitized Patients
- Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA Following Liver Transplantation
- Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
- Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
- Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- Everolimus Post Orthotopic Liver Transplant
- Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.
- Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients
- Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
- Kidney Graft Function Under the Immunosuppression Strategies
- Myfortic in High MELD Liver Transplantation
- Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS
- Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
- Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
- Study of Everolimus in de Novo Renal Transplant Recipients
- Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)
- Crohn's Allogeneic Transplant Study
- A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
- Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity
- Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation
- Scleroderma Treatment With Autologous Transplant (STAT) Study
- Efficacy of Certican® in Combination With Myfortic® in Renal
- Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
- Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
- Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients
- Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)
- Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study
- Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
- Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome
- Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study
- An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens
- Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
- A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
- Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
- Myfortic for the Treatment of Non-infectious Intermediate Uveitis
- Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
- Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation
- A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic
- Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus
- A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients
- The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
- Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
- Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program
- Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus Post Kidney Transplant: The Myfortic Study
- Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
- Impact of Myfortic on Gastrointestinal (GI) Prophylaxis in Maintenance Renal Transplant Patients
- Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
- Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
- Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
- A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
- Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
- Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol
- Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)
- Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
- Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
- Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
- Myfortic Conversion Trial in OLT Recipients With GI Intolerance
- Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors
- Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State
- Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
- Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
- Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
- Myfortic vs. Cellcept in Kidney Transplant Recipients
- Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
- Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen
- Myfortic Versus Azathioprine in Systemic Lupus Erythematosus
- Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms
- Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients
- A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
- Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
- Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
- Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients
- Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients
- Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients
- Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients
- Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal
- Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients
- Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
- Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients
- A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients
- Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.
- Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients
- Desensitization of Renal Transplant Candidates
- Myfortic - Treatment for Extensive cGvHD
- Steroid Free Immunosuppression in Liver Transplantation
- Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids
- Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients
- Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants
- Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
- Enteric Coated Myfortic for Liver Transplant Recipients
- Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients
- Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)
- Freedom Study: Myfortic in Kidney Transplant Patients
Clinical trials list
click for details